.
Total Voting Rights
April 1, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, in accordance with DTR 5.6.1 of the FSA's Disclosure
and Transparency Rules, notifies the market of the following:
At close of business on March 31, 2010, Shire plc's issued voting share capital
consisted of 562,092,533 ordinary shares with a nominal value of 5 pence. Each
ordinary share carries one voting right. Shire plc does not hold any shares in
Treasury.
The above figure (562,092,533) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Shire plc under the
FSA's Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations  Cléa Rosenfeld (Rest of the World)       +44 1256 894 160

                    Eric Rojas (North America)               +1 781 482 0999
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:
www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release

www.shire.com
END